A drug intended to treat menopause symptoms could double as breast cancer prevention. New research from Northwestern University in Illinois found that Duavee, a Pfizer-made drug, “significantly ...
Hosted on MSN
How weight gain after menopause triggers breast cancer, and how losing just 5-10% can protect you
Obesity has emerged as one of the most pressing global health issues, but for women approaching or undergoing menopause, its effects can be even more concerning. While most people associate obesity ...
A drug intended to treat menopause symptoms could double as breast cancer prevention. New research from Northwestern University in Illinois found that Duavee, a Pfizer-made drug, "significantly ...
Postmenopausal women with both CVD and obesity have a higher breast cancer risk than those with obesity alone. The study analyzed data from 168,547 women, revealing a stronger BMI-breast cancer risk ...
Hosted on MSN
Overlooked hormone may be deadly driver of postmenopausal breast cancer in women with obesity
A new analysis of research into the most common type of breast cancer has zeroed in on an overlooked hormone that may be responsible for the increased risk of breast cancer death in postmenopausal ...
A new analysis of research into the most common type of breast cancer has zeroed in on an overlooked hormone that may be responsible for the increased risk of breast cancer death in post-menopausal ...
Nearly every woman with breast cancer has at least one menopausal symptom. Yet many patients feel their quality-of-life needs ...
Women who undergo medical treatment for breast cancer are at greater risk for suffering from later vascular damage if they’ve already reached menopause, according to new data. Among the female ...
Cancer-related cognitive impairment (CRCI) is a long-term decline in thinking abilities that can happen after cancer or its treatment. Research shows that treatments like chemotherapy, radiation, ...
The effects of neoadjuvant chemotherapy in postmenopausal women on TSH and fT4, when compared with untreated postmenopausal women with breast cancer, are summarized in (c). Panel A highlights that ...
A 52-year-old woman, 3 years into aromatase inhibitor therapy for stage I hormone receptor–positive breast cancer, reports severe vasomotor symptoms, insomnia, brain fog, arthralgias, dyspareunia, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results